Māori with advanced non-small cell lung cancer are less likely to receive first line targeted therapy compared with non-Māori, according to a cohort study of patients in the New Zealand Midland Region between January 2011 and December 2021. The study included 2549 patients, of whom 775 (30%) were Māori. There was no difference between Māori and non-Māori in the overall rate of systemic anticancer therapy use. However, Māori were less likely to receive targeted therapy in the first-line setting (8.5% of patients vs 16.1% of non-Māori patients; p<0.01). Māori also had higher cancer-specific mortality (adjusted odds ratio 1.19; 95% confidence interval [CI] 1.08-1.32; p<0.001).
